Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$114.27 USD

114.27
224,037

-0.78 (-0.68%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (77 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Masimo's (MASI) solid product suite raises optimism about the stock.

Here's Why You Should Retain Molina (MOH) in Your Portfolio

by Zacks Equity Research

Numerous contract wins, financial flexibility and strong performing Medicaid and Medicare segments poise Molina (MOH) well for growth.

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Masimo (MASI) have performed compared to their sector so far this year.

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

by Zacks Equity Research

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Masimo's (MASI) Launch to Serve the Personalized Hearables Market

by Zacks Equity Research

Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.

Acadia Healthcare (ACHC) Expands With New Hospital in Michigan

by Zacks Equity Research

Acadia Healthcare's (ACHC) partnership with Bronson Healthcare to expand its footprint in Michigan with Bronson Behavioral Health Hospital.

Masimo (MASI) Inks Deals for Patient Monitoring Technologies

by Zacks Equity Research

Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.

Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.

Masimo (MASI) Down 6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Masimo's (MASI) New FDA Approval to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.

UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health

by Zacks Equity Research

UnitedHealth (UNH) offers to combine its Optum business with Amedisys to expand its reach in the healthcare-at-home market.

Here's Why Investors Should Hold Universal Health (UHS) Now

by Zacks Equity Research

Universal Health (UHS) benefits from growing patient volumes, sound segmental performance and a solid capital position.

Zacks Industry Outlook Highlights Hologic, Masimo and Integer

by Zacks Equity Research

Hologic, Masimo and Integer have been highlighted in this Industry Outlook article.

Masimo's (MASI) Platform Expansion to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Industry Challenges

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.

Down -16.93% in 4 Weeks, Here's Why Masimo (MASI) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Masimo (MASI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Masimo (MASI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Masimo (MASI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.

Masimo (MASI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 4.82% and 1.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 15.38% and 2.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Masimo (MASI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.